Viking Therapeutics is trading at $34.79 (+4.69%), primarily on broader biotech strength.
- XBI is up 2.06%, alongside a generally positive equity-market backdrop.
- No verified company-specific announcement has been identified for August 25, 2026.
- Investors may also be positioning ahead of Viking’s expected third-quarter VK2735 maintenance-dosing results, which management says are anticipated later in Q3. The catalyst remains sector-driven rather than a confirmed corporate release.